Robert Carey

Robert F.
Carey founded ACELYRIN, Inc. in 2020, where he worked as Chief Operating Officer & Director from 2020 to 2022.
Mr. Carey also currently works at Sangamo Therapeutics, Inc., as Independent Director from 2016, Hawthorne Race Course, Inc., as Director, Beyond Air, Inc., as Independent Director from 2019, Cour Pharmaceuticals Development Co., Inc., as Lead Independent Director from 2023, Beyond Air Ltd., as Director from 2019, Red Hen Corp., as Director, Suburban Downs, Inc., as Director, and Beyond Cancer, Ltd., as Director.
Mr. Carey also formerly worked at Dresdner Kleinwort Wasserstein, as Chief Executive Officer, Citizens JMP Securities LLC, as Managing Director from 2003 to 2014, Argos Therapeutics, Inc., as Independent Director from 2014 to 2018, FS Development Corp., as Independent Director from 2020 to 2021, Vector Securities International, Inc., as Managing Director from 1998 to 2001, Illinois Biotechnology Industry Organization, as Director, InStadium, Inc., as Director, Gemini Therapeutics, Inc., as Director from 2020 to 2021, Hyperion Therapeutics, Inc., as Chief Business Officer & Executive Vice President, Horizon Therapeutics Ltd. (Ireland), as Chief Business Officer & Executive Vice President from 2014 to 2019, Shearson Lehman Hutton, Inc., as Principal, Ernst & Whinney, as Principal, and Horizon Pharma, Inc., as Chief Business Officer & Executive Vice President from 2014 to 2019.
Mr. Carey received his undergraduate degree in 1981 from the University of Notre Dame.